|Bid||53.85 x 3100|
|Ask||53.87 x 3100|
|Day's range||53.54 - 54.05|
|52-week range||42.84 - 64.94|
|Beta (5Y monthly)||0.19|
|PE ratio (TTM)||35.51|
|Forward dividend & yield||1.40 (2.65%)|
|Ex-dividend date||25 Feb 2021|
|1y target est||63.60|
Yahoo Finance’s Anjalee Khemlani reports the latest developments on the coronavirus vaccines.
POSEIDON was a Phase III trial of AstraZeneca’s IMFINZI® (durvalumab) plus platinum-based chemotherapy or IMFINZI, tremelimumab and chemotherapy versus chemotherapy alone in the 1st-line treatment of patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC).
Dr. Oni Blackstock, Health Justice Founder & Executive Director, joined Yahoo Finance to discuss the latest on covid-19.